Mesoblast Limited American Depositary Shares (MESO)
Stock · NASDAQ · Health Care
$13.28as of 10/16/2026
Price chart
Active signals
MESO Signal Track Record
How signals performed across all stocks →What MESO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +2.7% | 60% | September 23, 2026 |
| Bollinger Band Breakout | 27 | +2.8% | 59% | July 13, 2026 |
| Bollinger Band Breakdown | 17 | -1.0% | 47% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -0.8% | 47% | September 9, 2026 |
| Any 20-session window (baseline) | +1.3% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MESO
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 108
- Website
- www.mesoblast.com/
Fundamentals
- 1-day range
- $13.5$13.91
- Market cap
- $2.02B
- P/E (trailing)
- —
- P/E (forward)
- 29.71
- EPS (trailing)
- $-0.04
- Dividend yield
- —
- Beta
- 1.03
- Avg. volume
- 212.5K
Forecasts
2 analyst ratings
Mesoblast Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- MESOMesoblast Limited American Depositary Shares$13.28▼ 4.80%Market cap $2.02BP/E —$1.88$3.31
- TSHATaysha Gene Therapies Inc. Common Stock$3.62▼ 2.95%Market cap $1.82BP/E —$3.46$7.3
- RVMDWRevolution Medicines Inc. Warrant$8.4▼ 13.98%Market cap $2.25BP/E —$0.2311$13.44
- VCELVericel Corporation Common Stock$40.13▼ 2.17%Market cap $2.29BP/E 85.09$28.95$49.32
- ADMAADMA Biologics Inc Common Stock$10.68▼ 0.47%Market cap $2.34BP/E 13.67$7.21$20.46
- RXRXRecursion Pharmaceuticals Inc. Class A Common Stock$3.46▼ 16.71%Market cap $1.69BP/E —$2.77$7.18
- BCRXBioCryst Pharmaceuticals Inc. Common Stock$7.79▼ 2.87%Market cap $2.36BP/E —$6.23$11.22
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MESO Mesoblast Limited American Depositary Shares | $2.02B | — | $13.28 | ▼ 4.80% | $1.88$3.31 |
| TSHA Taysha Gene Therapies Inc. Common Stock | $1.82B | — | $3.62 | ▼ 2.95% | $3.46$7.3 |
| RVMDW Revolution Medicines Inc. Warrant | $2.25B | — | $8.4 | ▼ 13.98% | $0.2311$13.44 |
| VCEL Vericel Corporation Common Stock | $2.29B | 85.09 | $40.13 | ▼ 2.17% | $28.95$49.32 |
| ADMA ADMA Biologics Inc Common Stock | $2.34B | 13.67 | $10.68 | ▼ 0.47% | $7.21$20.46 |
| RXRX Recursion Pharmaceuticals Inc. Class A Common Stock | $1.69B | — | $3.46 | ▼ 16.71% | $2.77$7.18 |
| BCRX BioCryst Pharmaceuticals Inc. Common Stock | $2.36B | — | $7.79 | ▼ 2.87% | $6.23$11.22 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Cochlear And 2 Australian Healthcare Stocks To WatchYahoo · 10/1/2026
- 3 Australian Founder Led Stocks With Revenue Growth Up To 37%Yahoo · 9/29/2026
- 3 Australian Growth Stocks With Earnings Growth Up To 65%Yahoo · 9/27/2026
- Elite Australian Owner Operator Stocks To Own In September 2026Yahoo · 9/25/2026
- Sector Update: Healthcare Stocks Advance Late AfternoonYahoo · 9/24/2026
- Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil ProductYahoo · 9/24/2026
- Mesoblast Receives FDA Approval To Implement A New Potency Assay, T-Cell Proliferation Inhibition Bioassay, For Release And Stability Monitoring Of All New Commercial Product Lots Of Its Mesenchymal Stromal Cell Product RyoncilBenzinga · 9/24/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 4.82M
- Total value held
- $73.50M
- Institutional holders
- 67
- Unknown851.3K
- Unknown714.6K
- Unknown630.9K
- Unknown545.4K
- Unknown514.4K
- Unknown397.2K
- Unknown132.6K
- Unknown100.0K
- Unknown87.1K
- Unknown83.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Mesoblast Included in Australian Healthcare Stock Lists
Mesoblast was featured in two recent Yahoo Finance articles highlighting Australian healthcare and growth stocks. These mentions provide visibility for the company within the broader market. The stock is currently trading near its 52-week range, with technical indicators showing a support rejection at $14.27.
Mesoblast Included in Australian Healthcare Stock Lists. Mesoblast was featured in two recent Yahoo Finance articles highlighting Australian healthcare and growth stocks. These mentions provide visibility for the company within the broader market. The stock is currently trading near its 52-week range, with technical indicators showing a support rejection at $14.27.